Ropack expands services with new plants; Compounder closes facility after FDA inspection;

> The FDA is warning providers not to use compounded drugs made by California's Park Compounding Pharmacy after an inspection found issues, leading to the voluntary closure of the facility while problems are resolved. Notice

> Lonza says it will create a scalable manufacturing process for Benitec Biopharma's gene-silencing technology. Report

> Canada's Ropack is rebranding as Ropack Pharma Solutions after buying two Forest Pharmaceutical plants that allow it to offer manufacturing operations in the U.S. Report

Suggested Articles

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back. 

The lawmakers question Kodak's fitness for such a major pharma manufacturing deal, as well as suspicious stock transactions by company leadership.

AZ's China COVID-19 vaccine deal comes after supply agreements with the U.S., the U.K., EU and Brazil, as well as licensing pacts in India and Japan.